NCT07312474 Epidemiological, Clinical and Biological Characteristics of Human Anaplasmosis Cases in Alsace
| NCT ID | NCT07312474 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Strasbourg, France |
| Condition | Human Anaplasmosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2024-10-02 |
| Primary Completion | 2026-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2024-10-02 with a primary completion date of 2026-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Anaplasmosis is a bacterial infection caused by the intracellular bacterium Anaplasma phagocytophilum and transmitted by ticks. This bacterium is present in approximately 1% of ticks in Alsace. This infection is responsible for clinical manifestations that are most often mild, including fever, headache, and myalgia, occurring 2 to 3 weeks after a tick bite. However, this infection can be accompanied by potentially serious or even fatal complications, including severe cytopenias, acute respiratory distress syndrome, septic shock, severe neurological disorders, hemorrhagic manifestations, macrophage activation syndrome, and multiple organ failure. Mortality is variable and appears to be higher in American studies, where it is around 4%. Treatment is well-established and relies on doxycycline, which is highly effective. Although a few cases have been described in France, these are mostly isolated cases or short series of cases, whereas Belgium, Poland, and Slovenia have reported numerous cases. Thus, there is a lack of data on French cases, and given that Alsace is in a region with a high prevalence of tick-borne diseases, data is needed to better understand the epidemiology and to better identify suspected cases in order to provide appropriate care.
Eligibility Criteria
Inclusion Criteria: * Adult subjct (≥18 years) * Presenting with a PCR-confirmed infection of Anaplasma Exclusion Criteria: \- Refusal to participate in the study
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07312474 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Human Anaplasmosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07312474 currently recruiting?
Yes, NCT07312474 is actively recruiting participants. Contact the research team at victor.gerber@chru-strasbourg.fr for enrollment information.
Where is the NCT07312474 trial being conducted?
This trial is being conducted at Strasbourg, France.
Who is sponsoring the NCT07312474 clinical trial?
NCT07312474 is sponsored by University Hospital, Strasbourg, France. The trial plans to enroll 100 participants.